← Eichor
Study identifier: NCT06296472 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

De Quervain's Disease in the Acute Phase:a Study Aimed at Evaluating the Effectiveness of Standard Physiotherapy Treatment (HANDGUIDE), Compared to Experimental Treatment After Performing Ultrasound-guided Infiltrative Therapy.

Condition: De Quervain Disease · Hand Tenosynovitis  ·  Sponsor: Istituto Ortopedico Rizzoli

PhaseNA
Planned participants134
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The objective of the study is to compare pain reduction and disability reduction in two groups of patients diagnosed with de Quervain syndrome who will undergo ultrasound-guided infiltrative treatment with corticosteroid as per normal clinical practice: * the control group will subsequently be subjected to a standard treatment based on the European guidelines of the HANDGUIDE group, * the experimental group will subsequently carry out a program of eccentric exercises.

This description comes directly from the study's public registry record.

Talk to the study team

Federico Pilla, MD  ·  0516366  ·  federico.pilla@ior.it

Fabio Vita, MD  ·  0516366  ·  fabio.vita@ior.it

Always discuss trial participation with your own doctor first.

Locations (1)

Istituto Ortopedico RizzoliBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06296472